September 15, 2026
FDA reduces monitoring time for Amgen’s Imdelltra infusions
The US Food and Drug Administration (FDA) has approved an update to the prescribing information for Amgen’s Imdelltra (tarlatamab-dlle), reducing the recommended monitoring time for patients with extensive-stage small cell lung cancer (ES-SCLC) after their first two infusions.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







